Vertex - מכפיל EV/Sales VRTX

לוגו של חברה ציבורית Vertex Pharmaceuticals Incorporated (VRTX)

Compliance with strict environmental standards and emissions filtration confirms the reliability of Vertex Pharmaceuticals (VRTX). This EV/Sales multiple chart demonstrates price stability, with the metric holding around 10149.49. Financial resilience is supported by a robust R&D budget to attract geneticists and the successful implementation of gene therapy, which effectively mitigates reliance on a single drug and reduces regulatory risks.

Vertex Pharmaceuticals - יחס שווי פעילות להכנסות VRTX (תקופה 23.11.2025 - 20.11.2026)

פילוחי מדדים פיננסיים ומדדי שוק עבור Vertex Pharmaceuticals Inc. (VRTX)

הערכת שווי פונדמנטלית של החברה:VRTX, vrtx.com
מוצר סדרתי של Vertex Pharmaceuticals Incorporated

Investors must find a compromise between minimizing undervaluation risks and maximizing return on invested capital. The monolithic management of Vertex Pharmaceuticals (VRTX) ensures this balance by scaling its R&D platform and successfully expanding beyond cystic fibrosis therapy. Analyzing the current EV/Sales ratio, which compares the total enterprise value to annual revenue excluding debt, confirms the high market resilience and strategic attractiveness of Vertex Pharmaceuticals (VRTX).